IP Library Granted Patent US 10,829,824
Granted Patent B2
US 10,829,824 · App. 14/927,785 · Granted Nov 10, 2020

Compositions, kits and methods for detection of campylobacter nucleic acid

Inventors: Michael R. Reshatoff, Jr. (San Diego, CA); Jennifer J. Bungo (San Diego, CA); Shannon K. Kaplan (San Diego, CA); James J. Hogan (Coronado, CA)
Assignee: GEN-PROBE INCORPORATED
C12Q1/689C12Q2600/158Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,829,824
App. No.
14/927,785
Granted
Nov 10, 2020
Kind
B2
Abstract

The disclosed invention is related to compositions, kits and methods comprising one or more oligomers targeting 16S rRNA target nucleic acid from Campylobacter species jejuni, coli and/or lari . Compositions include amplification oligomers, detection probe oligomers and/or target capture oligomers. Kits and methods comprise at least one of these oligomers.

Claims (19)

1. A composition for use in a Campylobacter target nucleic acid amplification assay, the composition comprising at least two amplification oligomers capable of stably hybridizing to a C. jejuni target nucleic acid and a C. coli , a C. lari or a C. coli and a C. lari target nucleic acid and amplifying a Campylobacter target nucleic acid in an amplification reaction, wherein a first of said amplification oligomers comprises a contiguous target hybridizing sequence 15 to 45 nucleotides in length and configured to hybridize to a sequence in a region of a Campylobacter 16S rRNA gene corresponding to nucleotides 108 to 150 of SEQ ID NO:91 and wherein a second of said amplification oligomers comprises a contiguous target hybridizing sequence 15 to 45 nucleotides in length and configured to hybridize to a sequence in a region of the a Campylobacter 16S rRNA gene corresponding to nucleotides 170 to 226 of SEQ ID NO:91, and wherein said first of said amplification oligomers is a promoter based amplification oligomer further comprising a 5′ promoter sequence.

2. The composition of claim 1 , wherein said second of said amplification oligomers comprises a target hybridizing sequence configured to hybridize to a sequence in a region of a Campylobacter 16S rRNA gene selected from the group consisting of: a region corresponding to nucleotides 170 to 212 of SEQ ID NO:91; a region corresponding to nucleotides 184 to 212 of SEQ ID NO:91; and a region corresponding to nucleotides 170 to 205 of SEQ ID NO:91.

3. The composition of claim 2 , wherein said first of said amplification oligomers comprises a target hybridizing sequence that consists essentially of SEQ ID NO:27.

4. The composition of claim 2 , wherein said first of said amplification oligomers comprises a sequence consisting of SEQ ID NO:26.

5. The composition of claim 2 , wherein said first of said amplification oligomers comprises a target hybridizing sequence selected from the group consisting of SEQ ID NOS:19, 21, 23, 25, 27, 29, 31 and 33.

6. The composition of claim 2 , wherein said first of said amplification oligomers comprises a sequence consisting of SEQ ID NO:32.

7. The composition of claim 1 , wherein said first of said amplification oligomers comprises a sequence that is selected from the group consisting of SEQ ID NOS:18, 20, 22, 24, 26, 28, 30, 32 and 84-88.

8. The composition of claim 1 , wherein said second of said amplification oligomers contains a target hybridizing sequence consisting of a sequence selected from the group consisting of SEQ ID NOS:1 through 14.

9. The composition of claim 8 , wherein said first of said amplification oligomers consists essentially of a sequence selected from the group consisting of SEQ ID NO:26 and SEQ ID NO:32.

10. The composition of claim 1 , wherein said second of said amplification oligomers consists essentially of a sequence of SEQ ID NO:7.

11. The composition of claim 1 , wherein said 5′ promoter sequence is SEQ ID NO:75.

12. The composition of claim 1 , further comprising a blocker oligomer wherein said blocker oligomer contains one or more blocking groups located at or near the 3′ end.

13. The composition of claim 1 , further comprising a detection oligomer comprising a sequence configured to hybridize to a portion of an amplification product generated from a target nucleic acid by said at least two amplification oligomers.

14. The composition of claim 13 , wherein said detection oligomer sequence is selected from the group consisting of SEQ ID NOS:63 through 68.

15. The composition of claim 13 , wherein said detection oligomer sequence consists essentially of SEQ ID NO:67 or consists essentially of SEQ ID NO:68.

16. The composition of claim 1 , wherein said first of said amplification oligomers comprises a sequence consisting essentially of a sequence selected from the group consisting of SEQ ID NO:26, SEQ ID NO:32, and SEQ ID NOS:84-88; and wherein said second amplification oligomer comprises a sequence consisting essentially of SEQ ID NO:7.

17. The composition of claim 16 , further comprising a detection oligomer comprising a sequence selected from the group consisting of SEQ ID NO:67 and SEQ ID NO:68.

18. The composition of claim 17 , wherein said first of said amplification oligomers comprises a sequence consisting essentially of a sequence selected from the group consisting of SEQ ID NO:26 and SEQ ID NO:32, and said composition further comprises a blocker oligomer comprises a sequence consisting of SEQ ID NO:50.

19. A reaction mixture containing the composition of claim 1 .

Assignments (7)
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 054089/0804 Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO FOCAL THERAPEUTICS, INC.; GEN-PROBE INCORPORATED; FAXITRON BIOPTICS, LLC; GEN-PROBE PRODESSE, INC.
Reel/Frame 075504/0575 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 037448/0348 Recorded Apr 23, 2026
From: BANK OF AMERICA, N.A. AS COLLATERAL AGENT
To: HOLOGIC, INC.; GEN-PROBE INCORPORATED
Reel/Frame 075467/0587 →
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
SECURITY INTEREST Recorded Oct 12, 2021
From: HOLOGIC, INC.; FAXITRON BIOPTICS, LLC; BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 057787/0526 →
SECURITY INTEREST Recorded Oct 15, 2020
From: HOLOGIC, INC.; FAXITRON BIOPTICS, LLC; FOCAL THERAPEUTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 054089/0804 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2017
From: RESHATOFF, JR., MICHAEL R.; BUNGO, JENNIFER J.; KAPLAN, SHANNON K.; HOGAN, JAMES J.
To: GEN-PROBE INCORPORATED
Reel/Frame 043820/0152 →
SECURITY AGREEMENT Recorded Jan 6, 2016
From: HOLOGIC, INC.; GEN-PROBE INCORPORATED
To: BANK OF AMERICA, N.A. AS COLLATERAL AGENT
Reel/Frame 037448/0348 →